Weihe Zhang

University of North Carolina at Chapel Hill — United States

Immunology and Microbiology · Life Sciences

21h-index1.9kcitations109works1.02yr avg

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Phagocytosis and Immune Regulation(54), Cancer, Hypoxia, and Metabolism(21), Metabolism, Diabetes, and Cancer(20), Cell death mechanisms and regulation(10), Cancer-related Molecular Pathways(9)

Publications109 total

Kinome profiling of non-Hodgkin lymphoma identifies Tyro3 as a therapeutic target in primary effusion lymphoma

UNC Libraries·2025Open Access

Absolute Configuration of Key Intermediates and the Gram Scale Synthesis of Berotralstat and ent- Berotralstat

The Journal of Organic Chemistry·2025

Activation of the bacterial defense-associated sirtuin system

Communications Biology·2025Open Access

Regioselective alkylation of a versatile indazole: Electrophile scope and mechanistic insights from density functional theory calculations

5 cited

Beilstein Journal of Organic Chemistry·2024· 5 citedOpen Access

The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia

UNC Libraries·2024Open Access

Effect of antiretroviral therapy on allele-associated Lp(a) level in women with HIV in the Women's Interagency HIV Study

UNC Libraries·2023Open Access

1522P Camrelizumab plus chemotherapy versus concurrent chemoradiotherapy as neoadjuvant therapy for resectable thoracic oesophageal squamous cell cancer (REVO): A multicenter, randomized, open-label, phase II trial

4 cited

Annals of Oncology·2023· 4 citedOpen Access

Supplementary Figure 3 from A Small-Molecule Inhibitor of Glucose Transporter 1 Downregulates Glycolysis, Induces Cell-Cycle Arrest, and Inhibits Cancer Cell Growth In Vitro and In Vivo

2023Open Access

Supplemental Figure 3 from Small Molecule Inhibition of MERTK Is Efficacious in Non–Small Cell Lung Cancer Models Independent of Driver Oncogene Status

2023Open Access

Supplemental Figure 1 from Small Molecule Inhibition of MERTK Is Efficacious in Non–Small Cell Lung Cancer Models Independent of Driver Oncogene Status

2023Open Access

Supplementary Figure 1 from A Small-Molecule Inhibitor of Glucose Transporter 1 Downregulates Glycolysis, Induces Cell-Cycle Arrest, and Inhibits Cancer Cell Growth In Vitro and In Vivo

2023Open Access

Supplemental Table 1 from Small Molecule Inhibition of MERTK Is Efficacious in Non–Small Cell Lung Cancer Models Independent of Driver Oncogene Status

2023Open Access

Data from A Small-Molecule Inhibitor of Glucose Transporter 1 Downregulates Glycolysis, Induces Cell-Cycle Arrest, and Inhibits Cancer Cell Growth In Vitro and In Vivo

2023Open Access

Supplementary Figure 1 from A Small-Molecule Inhibitor of Glucose Transporter 1 Downregulates Glycolysis, Induces Cell-Cycle Arrest, and Inhibits Cancer Cell Growth In Vitro and In Vivo

2023Open Access

Supplemental Figure 2 from Small Molecule Inhibition of MERTK Is Efficacious in Non–Small Cell Lung Cancer Models Independent of Driver Oncogene Status

2023Open Access

Supplementary Table 1 from A Small-Molecule Inhibitor of Glucose Transporter 1 Downregulates Glycolysis, Induces Cell-Cycle Arrest, and Inhibits Cancer Cell Growth In Vitro and In Vivo

2023Open Access

Supplementary Table 2 from A Small-Molecule Inhibitor of Glucose Transporter 1 Downregulates Glycolysis, Induces Cell-Cycle Arrest, and Inhibits Cancer Cell Growth In Vitro and In Vivo

2023Open Access

Supplementary Figure 3 from A Small-Molecule Inhibitor of Glucose Transporter 1 Downregulates Glycolysis, Induces Cell-Cycle Arrest, and Inhibits Cancer Cell Growth In Vitro and In Vivo

2023Open Access

Supplemental Table 1 from Small Molecule Inhibition of MERTK Is Efficacious in Non–Small Cell Lung Cancer Models Independent of Driver Oncogene Status

2023Open Access

Supplementary Figure Legend from A Small-Molecule Inhibitor of Glucose Transporter 1 Downregulates Glycolysis, Induces Cell-Cycle Arrest, and Inhibits Cancer Cell Growth In Vitro and In Vivo

2023Open Access

page 1 of 6Next →

Frequent Co-authors

Xiaodong Wang(25), Stephen V. Frye(24), H. Shelton Earp(23), Deborah DeRyckere(22), Douglas K. Graham(22), Michael A. Stashko(13), Dmitri Kireev(11), Susan Sather(10), Christopher T. Cummings(8), Debra M. Hunter(7), Jing Liu(7), Jacqueline Norris‐Drouin(7), Dehui� Zhang(6), William P. Janzen(6), Yi Liu(5), Stephen C. Bergmeier(5), Xiaozhuo Chen(5), Alisa B. Lee‐Sherick(5), Katherine A. Minson(4), Minjung Lee(4)